Okpete Uchenna E, Byeon Haewon
Department of Digital Anti-Aging Healthcare (BK21), Inje University, Gimhae 50834, South Korea.
World J Gastrointest Oncol. 2024 Nov 15;16(11):4528-4531. doi: 10.4251/wjgo.v16.i11.4528.
Cholangiocarcinoma (CCA), a highly aggressive bile duct cancer, is associated with late-stage diagnosis and limited treatment options, leading to poor patient outcomes. Early detection and personalized treatment strategies are crucial. The study by Wang highlights the prognostic potential of the PEA3 subfamily genes (, , and ) in CCA, identifying ETV4 as a particularly promising biomarker. Their bioinformatic analysis revealed that elevated expression correlates with poorer survival, positioning it as a strong indicator of disease progression. These findings suggest that ETV4 could enhance prognostic precision and guide personalized therapies, although further validation through large-scale clinical trials is essential. Challenges in clinical application include the need for comprehensive experimental validation and addressing the tumor heterogeneity in CCA. Future research should focus on validating these biomarkers in diverse cohorts and developing targeted therapies, especially in regions where CCA is endemic.
胆管癌（CCA）是一种侵袭性很强的胆管癌，与晚期诊断和有限的治疗选择相关，导致患者预后不良。早期检测和个性化治疗策略至关重要。王的研究强调了PEA3亚家族基因（、和）在CCA中的预后潜力，确定ETV4是一个特别有前景的生物标志物。他们的生物信息学分析表明，ETV4表达升高与较差的生存率相关，使其成为疾病进展的有力指标。这些发现表明，ETV4可以提高预后准确性并指导个性化治疗，尽管通过大规模临床试验进行进一步验证至关重要。临床应用中的挑战包括需要全面的实验验证以及解决CCA中的肿瘤异质性。未来的研究应专注于在不同队列中验证这些生物标志物并开发靶向治疗，特别是在CCA流行的地区。
